C4 THERAPEUTICS INC
C4 Therapeutics, Inc (CCCC) is a clinical‑stage biotechnology company focused on targeted protein degradation — small molecules designed to harness the cell’s protein disposal machinery to remove disease‑causing proteins. With a market capitalisation of roughly $228.5m, C4 is a small‑cap, research‑driven enterprise whose outlook hinges on clinical trial results, regulatory milestones and potential partnerships. Investors get exposure to an innovative therapeutic approach that could address previously “undruggable” targets, but that potential comes with high uncertainty: long development timelines, binary clinical outcomes, and ongoing funding needs that can dilute shareholders. Key considerations include the company’s pipeline progress, cash runway, collaborator agreements and the competitive landscape for degraders. This summary provides general educational information only and is not personalised investment advice; returns are not guaranteed and the value of shares can fall as well as rise.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying C4 Therapeutics' stock with a target price of $11.43, indicating good growth potential.
Financial Health
C4 Therapeutics is generating modest revenue and cash flow, but still has room for improvement.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
ACADIA PHARMACEUTICALS INC
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ADAPTIVE BIOTECHNOLOGIES CORP
Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company. The Company is focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. It applies its platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across its two business segments: Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic test, offered to clinicians. The IM business focuses on the discovery and development of transformative immune-based therapies in the treatment of patients with cancer and autoimmune diseases.
ABCELLERA BIOLOGICS INC
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
Why You’ll Want to Watch This Stock
Clinical milestones ahead
Upcoming trial readouts can move the stock substantially; positive data may unlock partnerships, though outcomes are binary and uncertain.
Novel therapeutic approach
Targeted protein degradation offers access to previously hard‑to‑drug targets, but scientific and regulatory hurdles remain.
Financing and runway
As a small‑cap biotech, C4 will likely need capital over time; that can enable development but may also dilute shareholders.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.